Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Gore

Showing results (101-110 of 138) with videos related to

Pageof 14
Sort By:
Molecular Cancer Therapeutics|October 22, 2015
Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell CarcinomaVictoria L Bridgeman, Elaine Wan, Shane Foo, et al.
Cancer Research|January 25, 2003
BRCA1/2 mutation status influences somatic genetic progression in inherited and sporadic epithelial ovarian cancer casesSusan J Ramus, Paul D P Pharoah, Patricia Harrington, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 11, 2007
Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high doseMichelle L Harrison, Eva Obermueller, Nick R Maisey, et al.
Gynecologic Oncology|July 15, 2014
A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinomaRichard T Penson, Kathleen M Moore, Gini F Fleming, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 26, 2006
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinomaMark J Ratain, Tim Eisen, Walter M Stadler, et al.
Hereditary Cancer in Clinical Practice|November 25, 2011
Screening for ovarian cancer in women with varying levels of risk, using annual tests, results in high recall for repeat screening testsMarielle Ae Nobbenhuis, Elizabeth Bancroft, Eleanor Moskovic, et al.
The Lancet. Gastroenterology & Hepatology|June 20, 2020
British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitisNick Powell, Hajir Ibraheim, Tim Raine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2009
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trialBernard Escudier, Tim Eisen, Walter M Stadler, et al.
The New England Journal of Medicine|January 12, 2007
Sorafenib in advanced clear-cell renal-cell carcinomaBernard Escudier, Tim Eisen, Walter M Stadler, et al.
The Journal of Pathology|October 15, 2013
Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomasMarco Gerlinger, Sergio A Quezada, Karl S Peggs, et al.
Pageof 14

Showing results (101-110 of 138) with videos related to

Sort By:
Pageof 14
Molecular Cancer Therapeutics|October 22, 2015
Preclinical Evidence That Trametinib Enhances the Response to Antiangiogenic Tyrosine Kinase Inhibitors in Renal Cell CarcinomaVictoria L Bridgeman, Elaine Wan, Shane Foo, et al.
Cancer Research|January 25, 2003
BRCA1/2 mutation status influences somatic genetic progression in inherited and sporadic epithelial ovarian cancer casesSusan J Ramus, Paul D P Pharoah, Patricia Harrington, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 11, 2007
Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high doseMichelle L Harrison, Eva Obermueller, Nick R Maisey, et al.
Gynecologic Oncology|July 15, 2014
A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinomaRichard T Penson, Kathleen M Moore, Gini F Fleming, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 26, 2006
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinomaMark J Ratain, Tim Eisen, Walter M Stadler, et al.
Hereditary Cancer in Clinical Practice|November 25, 2011
Screening for ovarian cancer in women with varying levels of risk, using annual tests, results in high recall for repeat screening testsMarielle Ae Nobbenhuis, Elizabeth Bancroft, Eleanor Moskovic, et al.
The Lancet. Gastroenterology & Hepatology|June 20, 2020
British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitisNick Powell, Hajir Ibraheim, Tim Raine, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 20, 2009
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trialBernard Escudier, Tim Eisen, Walter M Stadler, et al.
The New England Journal of Medicine|January 12, 2007
Sorafenib in advanced clear-cell renal-cell carcinomaBernard Escudier, Tim Eisen, Walter M Stadler, et al.
The Journal of Pathology|October 15, 2013
Ultra-deep T cell receptor sequencing reveals the complexity and intratumour heterogeneity of T cell clones in renal cell carcinomasMarco Gerlinger, Sergio A Quezada, Karl S Peggs, et al.
Pageof 14